[go: up one dir, main page]

WO2014008248A3 - Compositions and methods for treating and inhibiting viral infections - Google Patents

Compositions and methods for treating and inhibiting viral infections Download PDF

Info

Publication number
WO2014008248A3
WO2014008248A3 PCT/US2013/049046 US2013049046W WO2014008248A3 WO 2014008248 A3 WO2014008248 A3 WO 2014008248A3 US 2013049046 W US2013049046 W US 2013049046W WO 2014008248 A3 WO2014008248 A3 WO 2014008248A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compositions
papillomavirus
treating
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/049046
Other languages
French (fr)
Other versions
WO2014008248A2 (en
Inventor
Justice E. OBI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GRACELAND BIOTECHNOLOGY Inc
Original Assignee
GRACELAND BIOTECHNOLOGY Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/540,749 external-priority patent/US20140011837A1/en
Priority claimed from US13/687,273 external-priority patent/US20140011838A1/en
Priority claimed from US13/932,445 external-priority patent/US20140011839A1/en
Application filed by GRACELAND BIOTECHNOLOGY Inc filed Critical GRACELAND BIOTECHNOLOGY Inc
Priority to CN201380045847.5A priority Critical patent/CN104703601A/en
Priority to EP13813787.2A priority patent/EP2869821A4/en
Priority to CA2927146A priority patent/CA2927146A1/en
Publication of WO2014008248A2 publication Critical patent/WO2014008248A2/en
Publication of WO2014008248A3 publication Critical patent/WO2014008248A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Compositions and methods for the treatment, as well as the inhibition and prevention, of an infection of the papillomavirus and the epithelial lesions, namely, the warts of the skin and mucosal surfaces, associated therewith, in a mammalian host, as weil as methods of inhibiting the replication of a papillomavirus in an infected ceiL are provided. The compositions comprise a therapeutically effective amount of an active ingredient comprising at least one compound selected from the group consisting of chloroquine, hydroxychloroquine, amodiaquine, or in each case, a pharmaceutically acceptable salt thereof. The methods comprise topically administering a therapeutically and/or antivirally effective amount of such a compound to a mammalian host, such as a human being, in need of such treatment, although alternatively other routes of administration may be used, including but not limited to transdermal, transmucosal, respiratory, and by injection.
PCT/US2013/049046 2012-07-03 2013-07-02 Compositions and methods for treating and inhibiting viral infections Ceased WO2014008248A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN201380045847.5A CN104703601A (en) 2012-07-03 2013-07-02 Compositions and methods for treating and inhibiting viral infections
EP13813787.2A EP2869821A4 (en) 2012-07-03 2013-07-02 Compositions and methods for treating and inhibiting viral infections
CA2927146A CA2927146A1 (en) 2012-07-03 2013-07-02 Compositions and methods for treating and inhibiting viral infections

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US13/540,749 2012-07-03
US13/540,749 US20140011837A1 (en) 2012-07-03 2012-07-03 Compositions and methods for treating warts associated with viral infections
US13/687,273 2012-11-28
US13/687,273 US20140011838A1 (en) 2012-07-03 2012-11-28 Compositions and methods for treating warts associated with viral infections
US13/932,445 US20140011839A1 (en) 2012-07-03 2013-07-01 Compositions and methods for treating and inhibiting viral infections
US13/932,445 2013-07-01

Publications (2)

Publication Number Publication Date
WO2014008248A2 WO2014008248A2 (en) 2014-01-09
WO2014008248A3 true WO2014008248A3 (en) 2014-02-27

Family

ID=49882589

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2013/049046 Ceased WO2014008248A2 (en) 2012-07-03 2013-07-02 Compositions and methods for treating and inhibiting viral infections

Country Status (4)

Country Link
EP (1) EP2869821A4 (en)
CN (1) CN104703601A (en)
CA (1) CA2927146A1 (en)
WO (1) WO2014008248A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2544153B1 (en) 2014-02-24 2016-06-06 Ntd Labs, S.L. Use of a casein hydrolyzate as an antiviral agent
CN104352495A (en) * 2014-11-15 2015-02-18 广州凯普生物科技有限公司 Medicine for treating wart diseases
WO2018191642A1 (en) * 2017-04-13 2018-10-18 Texas Biomedical Research Institute Novel amodiaquine analogs and methods of uses thereof
KR20210044805A (en) 2018-08-06 2021-04-23 닐슨 바이오사이언스, 아이엔씨. Wart treatment
CN109288816B (en) * 2018-12-04 2019-11-22 广州凯普医药科技有限公司 A kind of chloroquine gel and its preparation method and application
CN110917196B (en) * 2020-02-05 2020-06-05 广州康健医学科技有限公司 Chloroquine antibacterial disinfectant and application thereof
CN112089841A (en) * 2020-04-05 2020-12-18 徐静 Pharmaceutical composition for treating diseases caused by virus infection of epithelial tissues
CN115397402A (en) * 2020-04-14 2022-11-25 格兰尼斯制药公司 Transdermal and/or topical delivery system comprising hydroxychloroquine and/or chloroquine
CN114848642A (en) * 2022-07-07 2022-08-05 广州康健医学科技有限公司 Application of chloroquine phosphate in preparation of medicine for preventing and treating high-risk HPV infection, cervical cancer precursor lesion and cervical cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680308B1 (en) * 1998-04-14 2004-01-20 Jomaa Hassan Use of organophosphorus compounds for the therapeutic and prophylactic treatment of infections
US8158677B2 (en) * 2007-06-01 2012-04-17 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6680308B1 (en) * 1998-04-14 2004-01-20 Jomaa Hassan Use of organophosphorus compounds for the therapeutic and prophylactic treatment of infections
US20040082549A1 (en) * 1998-04-14 2004-04-29 Hassan Jomaa Use of organophosphorus compounds for the therapeutic and prophylactic treatment of infections
US8158677B2 (en) * 2007-06-01 2012-04-17 The Trustees Of Princeton University Treatment of viral infections by modulation of host cell metabolic pathways

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2869821A4 *

Also Published As

Publication number Publication date
CA2927146A1 (en) 2014-01-09
WO2014008248A2 (en) 2014-01-09
EP2869821A2 (en) 2015-05-13
EP2869821A4 (en) 2016-04-06
CN104703601A (en) 2015-06-10

Similar Documents

Publication Publication Date Title
WO2014008248A3 (en) Compositions and methods for treating and inhibiting viral infections
SA519402405B1 (en) HIV inhibitor compounds
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2012065963A3 (en) Antiviral condensed heterocyclic compounds
IN2015DN04175A (en)
WO2013123215A3 (en) Antiviral drugs for treatment of arenavirus infection
SI2932970T1 (en) Antiviral therapy
WO2012027712A3 (en) Potent and selective inhibitors of hepatitis c virus
WO2019244066A3 (en) Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication
BR112015014458A2 (en) mannose derivatives for the treatment of bacterial infections
HK1209638A1 (en) Pharmaceutical compositions
BR112015003188A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, COMPOUND USE, AND METHOD FOR TREATMENT OF A RORGAMMAT-MEDIATED DISEASE OR CONDITION IN A PATIENT
WO2013059559A3 (en) Compounds and methods for enhancing innate immune responses
EA201491479A1 (en) DERIVATIVES OF LUPANOV TRITERPENOIDS AND THEIR PHARMACEUTICAL APPLICATIONS
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
HK1198869A1 (en) Combination treatments for hepatitis c
WO2014134583A3 (en) Methods of treatment of human cytomegalovirus infection and diseases with bromodomain inhibitors
CA2862755A1 (en) Antiviral compounds with a dibenzooxaheterocycle moiety
PH12015502406A1 (en) Orally administrable pharmaceutical composition for prevention or treatment of dry eye syndrome, comprising rebamipide or prodrug thereof
FR2961695B1 (en) USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SKIN DISORDERS
PH12014501601A1 (en) Artemisinin-based combination therapy for treating viral mediated disease
MX2021015441A (en) Crystalline forms of cabotegravir sodium.
IN2013CH05288A (en)
WO2014140680A8 (en) Dosing regimen for use of celgosivir as an antiviral therapeutic for dengue virus infection
WO2014122537A3 (en) Pharmaceutical compositions and methods of treating hepatitis c virus infection using a combination of hydroxychloroquine and ribavirin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13813787

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013813787

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2927146

Country of ref document: CA